Stock comparison
ResMed
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 71B | RMD |
| Benjamin Graham | 75B | 76B | UTHR |
| Philip Fisher | 75B | 76B | UTHR |
| Peter Lynch | 58C | 62C | UTHR |
| Joel Greenblatt | 47D | 46D | RMD |
| Charlie Munger | 69B | 64C | RMD |
| Terry Smith | 73B | 64C | RMD |
Side-by-side metrics
| Metric | RMD | UTHR |
|---|---|---|
| Market cap | $30.18B | $24.13B |
| P/E (TTM) | 19.6x | 19.2x |
| EV/EBIT | 17.1x | 15.2x |
| ROIC (TTM) | 19.63% | 18.81% |
| Gross margin | 61.69% | 86.58% |
| Net margin | 27.44% | 40.61% |
| Revenue CAGR 5y | 12.64% | 17.22% |
| EPS CAGR 5y | 30.73% | 29.84% |
| Debt / Equity | 0.1x | - |
| Dividend yield | 1.14% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $24.13B+20%
UTHR leads on
- Debt / Equity-vs 0.1x+100%
- Net margin40.61%vs 27.44%+32%
- Gross margin86.58%vs 61.69%+29%
- Revenue CAGR 5y17.22%vs 12.64%+27%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.